Welcome to our dedicated page for Edwards Lifesciences SEC filings (Ticker: EW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edwards Lifesciences Corporation filings document regulatory disclosures for a Delaware medical technology company with common stock listed on the New York Stock Exchange under EW. Recent Form 8-K reports furnish quarterly and annual operating results, including sales commentary tied to transcatheter aortic valve replacement and transcatheter mitral and tricuspid therapies.
Proxy and material-event filings cover board elections, executive compensation, shareholder voting results, amendments to the Long-Term Stock Incentive Compensation Program, and senior finance leadership changes. These records also identify the company’s registered common stock structure and formal governance matters submitted to stockholders.
Edwards Lifesciences Corp corporate vice president Annette Bruls reported a routine tax-related share disposition. On 2026-07-11, 109 shares of common stock were withheld at $92.21 per share to satisfy tax withholding obligations tied to vesting under Rule 16b-3(e). Following this withholding, she holds 20,628 shares of Edwards Lifesciences common stock directly.
Mistras Theodora reported acquisition or exercise transactions in this Form 4 filing.
Edwards Lifesciences Corp reported that its CVP, Chief Financial Officer Theodora Mistras received multiple equity awards on July 9, 2026 under the company’s Long-Term Stock Incentive Compensation Program. The awards include restricted stock units, performance-based restricted stock units, and employee stock options with multi‑year vesting schedules tied to continued service and, for the performance units, achievement of specified performance goals.
Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 619 shares of common stock at $72.68 per share and, in a related open-market transaction, sold 619 shares at $91.70 per share on July 10, 2026. Following these transactions, he holds 40,033.9103 common shares directly and 4,952 employee stock options. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026.
Edwards Lifesciences Corp executive Daniel J. Lippis reported a small, routine share disposition tied to tax withholding. On the vesting of equity awards, the issuer withheld 377 shares of common stock at $95.18 per share to cover tax obligations under Rule 16b-3(e).
After this tax-withholding event, Lippis directly holds about 40,033.9103 shares of Edwards Lifesciences common stock. The transaction reflects compensation-related tax settlement rather than an open-market sale or a change in his investment stance.
Edwards Lifesciences Corp corporate vice president Daniel J. Lippis exercised and sold a small block of shares under a pre-planned program. He exercised employee stock options to acquire 619 shares of common stock at $72.68 per share, then sold 619 shares in an open-market sale at a weighted average price of $91.4002 per share.
The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2026, indicating they were pre-scheduled. After these trades, Lippis directly holds about 40,410.9103 shares of common stock and 5,571 employee stock options.
Edwards Lifesciences Corp CEO Bernard J. Zovighian reported an open-market sale of 523 shares of Common Stock at $87.92 per share. The shares were held indirectly through a trust, which held 11,516.5511 shares after the transaction.
The filing also shows 3,733.5603 shares held indirectly through a 401(k) plan and 99,164.6499 shares held directly as of the same date. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 12, 2025, indicating it was scheduled in advance.
Edwards Lifesciences Corp executive Theodora Mistras, who serves as CVP and Chief Financial Officer, filed an initial Form 3 ownership report. The filing does not list any transactions or derivative positions and serves mainly to identify her role and status as a reporting person for the company.
Edwards Lifesciences Corp senior vice president and corporate controller Andrew M. Dahl reported an open-market sale of Common Stock. He sold 567.5266 shares at a price of $86.08 per share and now directly holds 15,334.0948 shares, indicating a relatively small reduction in his position.
Edwards Lifesciences Corp. notice reports proposed sales of Common Stock by an affiliate under equity compensation. The filing shows Scott B. Ullem with sales of 13,000 shares on 03/11/2026 ($1,103,896.00) and 13,000 shares on 04/09/2026 ($1,040,544.00). The securities column references RSU / PSU awarded 05/12/2019.
Edwards Lifesciences submitted a Form 144 disclosing a proposed sale of common stock through Charles Schwab & Co. The filing lists transaction dates 02/22/2025 and 06/28/2024, and shows a filing/processing date of 05/29/2026. The entry references restricted‑stock lapse and an ESPP disposition.